Bayer is seeking to expedite it’s patient safety data monitoring through artificial intelligence (AI) in an initiative that it hopes will enable any drug-associated side effects to be spotted earlier.
The German-based pharmaceutical has partnered with Genpact, a professional services company for this work through signing an agreement for several years for its pharmacovigilance AI products.
According to Bayer, such efforts will help in reinforcing its commitment to patient safety.
Bayer’s Global Head of pharmacovigilance for consumer health and pharmaceuticals said: “With Genpact, we have found a partner whose innovative capabilities in the area of applying advanced AI and machine learning technologies to pharmacovigilance provide us with an opportunity to further increase the efficiency of our pharmacovigilance operating model and case processing while maintaining our high quality and compliance standards.”
Genpact asserted that its PVAI solution that draws severe event data from various source documents in an automated manner, has participated, and won, several highly competitive proof-of-concept exercises undertaken by big pharmaceutical firms.
Genpact’s Business Leader of Life Sciences and Healthcare Balkrishan ‘BK’ Kalra said: “We believe the ability to apply advanced AI technologies, with significant process and domain expertise, will usher in a whole new era of pharmacovigilance by serving as a single machine learning system that can be utilized across the industry by life sciences companies, healthcare providers, and regulators”.
“We expect safety issues can be identified more rapidly, and resources can be freed up to focus on advanced and effective risk minimization measures. We are thrilled to be working with Bayer to leverage their excellence in Pharmacovigilance and together create a better future with increased collaboration across the healthcare ecosystem.”
Bayer ’s partnership with Genpact introduces a new ground for the use of AI by pharmaceutical companies.
In fact, until today the focus has been on enhancing patient outcomes, as is observed during the collaboration between IBM Watson and Novartis.